Positive Results for Janssen’s Phase ||| optimum study.

Positive results have been reported by Janssen from its phase ||| optimum study which has evaluated the efficacy and safety of ponesimod in in adults with relapsing multiple sclerosis.

The drug is believed to inhibit S1P activity as well as reduce the number of lymphocytes circulating by trapping them in the lymph nodes.

Meeting its primary and secondary end points (annualised relapse rate up to the end of the study and a change from baseline to week 1008 in fatigue related symptoms) the study was also able to evaluate cumulative number of combine unique action lesions, time to first 12 week confirmed disability accumulation and time to first 24 week confirmed disability accumulation.
Data from this phase will be presented to the U.S. Food and Drug Administration and European Medicines Agency for approval.